Alloway Advised FDA at Public Hearing
On June 21, Rita Alloway, PharmD, research professor in the division of nephrology and hypertension, participated in a Food and Drug Administration public hearing, "Generic Drug User Fee Amendments of 2012 Regulatory Science initiatives: Request for Public Input for FY 2014 Generic Drug Research The Food and Drug Administration.
Alloway represented the American Society of Transplantation to advise the FDA related to future research efforts in generic drug use in transplantation. In addition to reviewing the status of the currently FDA funded U01, she provided specific study recommendations for future studies.
Tags
Related Stories
UC radiation oncologist speaks with Local 12 news about clinical trial for head and neck cancer treatment
August 10, 2026
Dr. Sara Medek, a UC radiation oncology professor, speaks with Local 12 news about a new clinical trial aimed at reducing radiation in certain areas while still treating cancer effectively but with fewer painful side effects.
Cancer Center director charts future based on collaboration, AI
August 10, 2026
David Gius, MD, PhD, was featured in a Cincinnati Business Courier article and The Cancer Letter’s “The Directors" podcast discussing his priorities and goals as he recently took the helm as director of the University of Cincinnati Cancer Center.
Bidirectional link between oral, kidney health calls for patient education, access
August 4, 2026
Despite growing awareness of the connection between oral health and chronic health conditions, patient awareness and access to dental care remain limited, according to University of Cincinnati experts who recently spoke with Healio | Nephrology News & Issues.